We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

76 hedge funds and large institutions have $397M invested in Krystal Biotech in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 11

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

78% more capital invested

Capital invested by funds: $223M → $397M (+$174M)

33% more funds holding

Funds holding: 57 → 76 (+19)

11.48% more ownership

Funds ownership: 46.53% → 58.01% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
76
Holders Change
+19
Holders Change %
+33.33%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
30
Increased
26
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$24.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$20.4M
3
O
OrbiMed
New York
+$19.1M
4
BlackRock
BlackRock
New York
+$17.9M
5
BBA
Baker Bros. Advisors
New York
+$8.17M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$16.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.85M
3
SFM
Sphera Funds Management
Israel
-$2.09M
4
KCM
Knoll Capital Management
Florida
-$2.06M
5
ECM
Endurant Capital Management
California
-$2.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$1.61M +$607K +18,560 +87%
Squarepoint
27
Squarepoint
New York
$1.59M +$1.07M +32,777 +493%
N
28
Nuveen
North Carolina
$1.42M +$1.15M +35,182 New
MIM
29
Monashee Investment Management
Massachusetts
$1.41M +$1.14M +35,000 New
EGI
30
EAM Global Investors
California
$1.33M +$1.08M +33,137 New
Acadian Asset Management
31
Acadian Asset Management
Massachusetts
$1.32M +$423K +12,953 +66%
ACH
32
ArrowMark Colorado Holdings
Colorado
$1.23M – – –
PPA
33
Parametric Portfolio Associates
Washington
$1.22M +$992K +30,334 New
AA
34
ALPS Advisors
Colorado
$1.22M -$151K -4,623 -13%
Allianz Asset Management
35
Allianz Asset Management
Germany
$1.02M -$323K -9,874 -28%
Morgan Stanley
36
Morgan Stanley
New York
$1M +$752K +23,002 +1,201%
Charles Schwab
37
Charles Schwab
California
$840K +$681K +20,839 New
Swiss National Bank
38
Swiss National Bank
Switzerland
$826K +$670K +20,500 New
TD Asset Management
39
TD Asset Management
Ontario, Canada
$808K +$389K +11,902 +146%
RWM
40
Ritholtz Wealth Management
New York
$782K – – –
William Blair & Company
41
William Blair & Company
Illinois
$776K -$1.53M -46,940 -71%
JP Morgan Chase
42
JP Morgan Chase
New York
$741K +$421K +12,891 +195%
Neuberger Berman Group
43
Neuberger Berman Group
New York
$636K +$206K +6,300 +66%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$604K +$276K +8,432 +128%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$543K +$441K +13,491 New
SEI Investments
46
SEI Investments
Pennsylvania
$487K +$396K +12,101 New
MF
47
Magnetar Financial
Illinois
$483K +$392K +12,000 New
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$461K +$112K +3,441 +43%
BTS
49
BB&T Securities
Virginia
$442K – – –
Barclays
50
Barclays
United Kingdom
$440K -$819K -25,048 -70%
1
2
3 4

KRYS Hedge Fund Activity: Q2 2019 in Review

76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2019, worth a combined $397M — up 78% from $223M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KRYS positions and 11 closed out — a net gain of 19 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Redmile Group, adding an estimated $24.7M. The largest seller was Great Point Partners, exiting entirely with an estimated $16.2M sold.

  • 76 institutional investors held Krystal Biotech (KRYS) as of Q2 2019, up from 57 in Q1 2019.
  • Funds reported $397M of Krystal Biotech stock for Q2 2019, up 78% quarter-over-quarter.
  • 30 funds opened new Krystal Biotech positions in Q2 2019 and 11 closed out, a net change of +19 holders.
  • The largest Krystal Biotech buyer in Q2 2019 was Redmile Group, an estimated $24.7M added.
  • The largest Krystal Biotech seller in Q2 2019 was Great Point Partners, an estimated $16.2M sold.

Based on aggregated 13F filings for Q2 2019.